Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on WORKSPACE GROUP PLC. We currently have 18 research reports from 2 professional analysts.
|28Feb17 13:12||RNS||Director Declaration|
|28Feb17 07:00||RNS||CAPITAL MARKETS EVENT|
|20Feb17 15:20||RNS||Voting Rights and Share Capital|
|02Feb17 07:00||RNS||Holding(s) in Company|
|31Jan17 07:30||RNS||Notification of major interest in shares|
|27Jan17 07:00||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
WORKSPACE GROUP PLC
WORKSPACE GROUP PLC
Panmure Morning Note 22-01-16
22 Jan 16
The pace of growth achieved by Workspace over the last two years has been extraordinary and today's operating metrics suggest that the group will meet our new FY16E forecasts. The total rent roll is growing at an annualised rate of 16.4%. Our upgrades to earnings reflect the continued strong results and represent a CAGR of 25.5% between FY15A-FY18E. The group has positioned itself defensively with a very strong balance sheet but has also embraced the future providing contemporary working environments for which demand should remain robust. The share price has been particularly badly hit in the current rout (-14.6% YTD) so that the shares are now trading 3.4% above the historic NAV of 792p. Our Target Price of 1074p reflects the one year forward forecast total return and we retain our BUY recommendation.
Panmure Morning Note 11-11-15
11 Nov 15
Workspace is benefiting from a confluence of strong drivers so that the group is producing excellent results. Today's figures do not disappoint. The strength of the SME sector in London, the underlying rental appreciation due to supply constraints and the underlying low base rents have led strong results and management confidence in the momentum is underpinned by the 25% increase in dividend. Competition is growing in the temporary leasing market but the models differ from Workspace in type of offer and target customer. Importantly most are not landlords and so have to compensate for the duration risk with higher rents. We continue to expect the group to generate strong growth over the next two years and so increase our TP to 1074p, a 20% premium of our T+1 NAV/s plus dividend. BUY.
Panmure Morning Note 23-10-15
23 Oct 15
The two acquisitions this morning add to the immediate letting pipeline for the group. Surrey Quays and Alexandra House (in Wood Green) will provide refurbishment opportunities into 2021 while providing solid income in the near term. We have upgraded our estimates since the strong FY15A and 1Q16 figures and retain our target price of 1010p and BUY recommendation.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.